Ironwood Pharmaceuticals, Inc. IRWD

4.13 (0.06) (1.43%) as of 25 Sep
Market cap
$692.4M
P/E
5.2×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
296.15 351.41 442.74 410.60 413.75 389.52 428.41 346.64 298.28 273.96
Revenue Growth
(15.72%) (20.63%) 7.83% (0.76%) 6.22% (9.08%) 23.59% 16.21% 8.88% 83.18%
Cost of Revenue
— — — 1.42 1.52 3.14 23.88 32.75 19.10 1.87
Gross Profit
296.15 351.41 442.74 410.60 413.75 386.39 404.54 313.89 279.18 272.09
R&D Expenses
95.14 111.42 1,211.53 44.27 70.41 88.06 115.04 101.06 88.15 139.49
SG&A Expenses
82.26 144.27 158.31 115.99 111.13 140.00 172.45 219.68 231.18 173.28
Operating Income
98.50 93.12 (945.43) 250.34 232.26 142.94 120.12 (150.67) (15.36) (51.87)
Non-operating Income/Expense
(28.48) (27.93) (2.64) 2.09 (31.60) (34.08) (61.18) (43.48) (39.55) (29.84)
Non-operating Interest Expenses
32.75 33.03 21.63 7.60 31.15 29.48 36.60 37.72 36.37 39.15
EBT
70.03 65.20 (948.07) 252.42 200.66 108.86 58.94 (194.15) (54.91) (81.71)
Income Tax Provision
46.01 64.32 83.49 77.36 (327.79) 2.69 — — — —
Income after Tax
24.02 0.88 (1,031.56) 175.07 528.45 106.18 58.94 (194.15) (54.91) (81.71)
Dividends (Preferred)
— — 0.00 — — — — — — —
Non-Controlling Interest
— — (29.32) — — — — — — —
Net Income Common
24.02 0.88 (1,002.24) 175.07 528.45 106.18 21.51 (282.37) (116.94) (81.71)
EPS (Basic)
0.15 0.01 (6.45) 1.13 3.26 0.67 0.14 (1.85) (0.78) (0.56)
EPS (Diluted)
0.15 0.01 (6.45) 0.96 3.21 0.66 0.14 (1.85) (0.78) (0.56)
Shares (Basic, Weighted)
161.84 159.08 155.44 154.37 162.25 159.43 156.02 152.63 148.99 144.93
Shares (Diluted, Weighted)
162.98 160.08 155.44 186.31 164.42 160.66 156.02 152.63 148.99 144.93
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 99.19% 94.43% 90.55% 93.60% 99.32%
EBIT Margin
33.26% 26.50% (213.54%) 60.97% 56.13% 36.70% 28.04% (43.47%) (5.15%) (18.93%)
EBT margin
23.65% 18.55% (214.14%) 61.48% 48.50% 27.95% 13.76% (56.01%) (18.41%) (29.83%)
Net Profit Margin
8.11% 0.25% (226.37%) 42.64% 127.72% 27.26% 5.02% (81.46%) (39.20%) (29.83%)
Free Cash Flow Margin
42.89% 29.43% 41.37% 66.64% 63.23% 42.87% 0.89% (20.10%) (34.67%) (47.42%)
EBITDA
100.38 95.14 (943.85) 251.76 233.78 146.50 125.70 (138.70) (2.71) (40.61)
EBIT
98.50 93.12 (945.43) 250.34 232.26 142.94 120.12 (150.67) (15.36) (51.87)
Income from Continuous Operations
24.02 0.88 (1,031.56) 175.07 528.45 106.18 58.94 (194.15) (54.91) (81.71)
Income from Discontinued Operations
— — — — — — (37.44) (88.22) (62.02) —
Consolidated Net Income/Loss
24.02 0.88 (1,031.56) 175.07 528.45 106.18 21.51 (282.37) (116.94) (81.71)
EPS (Basic, from Continuous Ops)
0.15 0.01 (6.64) 1.13 3.26 0.67 0.38 (1.27) (0.37) (0.56)
EPS (Basic, from Discontinued Ops)
— — — — — — (0.24) (0.58) (0.42) —
EPS (Basic, Consolidated)
0.15 0.01 (6.64) 1.13 3.26 0.67 0.14 (1.85) (0.78) (0.56)
EPS (Diluted, from Cont. Ops)
0.15 0.01 (6.64) 0.94 3.21 0.66 0.38 (1.27) (0.37) (0.56)
EPS (Diluted, from Disc. Ops)
— — — — — — 0.00 0.00 0.00 —
Shares (Diluted, Average)
162.98 159.08 155.44 186.31 164.42 160.66 153.61 152.63 148.99 144.93
EPS (Diluted, Consolidated)
0.15 0.01 (6.64) 0.94 3.21 0.66 0.14 (1.85) (0.78) (0.56)
EBITDA Margin
33.90% 27.07% (213.19%) 61.31% 56.50% 37.61% 29.34% (40.01%) (0.91%) (14.82%)
Operating Cash Flow Margin
42.90% 29.47% 41.43% 66.67% 63.30% 43.34% 2.50% (20.45%) (33.78%) (9.47%)

Fold the line items

In millions of $ except per-share values · columns are period end dates